Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib DDI Study with CYP450/Transporter Substrates
NCT05657613Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pacritinib in myelofibrosis (MF) (3 arms), sponsored by CTI BioPharma Corp. Primary endpoints: Area Under the Curve at 14 days and Maximum Plasma Concentration at 14 days. Started Jan 2023; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05657613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657613.